There are up to 80 ADCs in clinical development with close to 600 ongoing trials.
The association between functional impairment and symptom burden was shown to be predictive of outcomes for older patients with advanced cancer.
Physicians should frame treatment options by their “harms and benefits,” not by their “risks and benefits.”
Although numerous clinical studies have aimed to treat AML, most results have been disappointing, according to authors of a publication in Blood.
The current state of AML treatment and remaining needs are discussed in an interview with Courtney D. DiNardo, MD, MSCE and Ghayas C. Issa, MD.
An assay from Mayo Clinic researchers screens multiple myeloma drugs to see how cells with different biomarkers and pretreatment histories react.
The American Society of Clinical Oncology published new clinical guidelines on the management of cachexia in adults with advanced cancer.
New developments in lab assays have allowed for more specialized assessments of VWD activity, leading to better diagnoses and various treatment options.
Investigators discuss surgical approaches and outcomes of total and partial splenectomy for the treatment of hereditary hemolytic anemia in children.
A EULAR task force developed recommendations for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy.
A review of techniques oncology nurses can use to help themselves cope with their feelings as they navigate through the effects of the COVID-19 pandemic on their practice, their patients, and themselves.
Families affected by the emotional burden of childhood cancer often face significant financial difficulty due treatment expenses and time away from work.
Expertise in the use of nonpharmacologic pain management techniques and therapies allow masters-prepared social workers to be an integral member of a multidisciplinary cancer care team.
ASH published new clinical guidelines on the prevention, diagnosis, and treatment of CNS complications for children and adults with sickle cell disease.
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
ILROG has issued guidelines on alternative radiation treatment methods to combat limited treatment resources for cancer patients during the COVID-19 pandemic.
IL-6 blockade may have helped a patient with multiple myeloma recover from COVID-19, but larger studies are needed to prove efficacy.
Approximately 30% of patients with hemophilia are considered sporadic cases, causing a challenge when determining carrier status and disease transmission risk to offspring.
The use of telemedicine has been surging since the onset of COVID-19, with millions of Americans now using this medium for connecting with their clinicians.
An expert panel of clinicians developed guidelines for the use of rituximab in the maintenance of remission for adult ANCA-associated vasculitis.
Hydroxychloroquine is a less-toxic metabolite of the antimalarial drug chloroquine and is used as an immunomodulator for the treatment of autoimmune diseases.
Survival outcomes are relatively high for children with ALL but genetics, insufficient chemotherapy treatment, and the risk of relapse may factor into the reduced survival outcomes in adult patients.
Transgender patients present unique communication as well as clinical challenges for oncology clinicians.
An expanding range of treatment options in the past decade has led to greater long-term survival in patients with multiple myeloma.
Some US medical centers have canceled treatments and all centers have altered their policies and procedures out of precaution related to the COVID-19 pandemic.
A review of case studies that outline treatment decisions based on patient and disease characteristics.
During a routine physical examination, a clinician suspects May-Hegglin anomaly because of the patient’s low platelet count and hearing loss.
Older adults are often underrepresented in trials either because of comorbidities that cause them to be excluded, or through unconscious bias on the part of study teams.
How should clinicians combat coronavirus disease (COVID-19) in their practice settings?
Although some patients with cancer are at higher risk of developing severe disease should they become infected, these experts suggest the precautions being given to the general population are sufficient — at least for now.
Researchers provided an overview of toxicities associated with the use of novel agents to treat hematologic malignancies, as well as potential management strategies.
A panel of researchers developed evidence-based guidelines to support clinical decision making regarding transfusion support for patients with sickle cell disease.
As the life expectancy for patients with beta thalassemia continues to increase, more and more patients are experiencing age-related complications.
Treatment regimens including immunomodulatory agents or proteasome inhibitors could lead to development of peripheral neuropathy.
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Several factors need to be considered when choosing optimal therapy for older patients with hematologic malignancies, particularly when it comes to managing toxicity.
Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
Researchers reviewed the diagnosis and management of several pregnancy-specific causes of thrombocytopenia.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Although gene therapy shows promise in curing hemophilia, questions about its efficacy, optimal administration, and outcomes remain.
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
Researchers reviewed currently available point-of-care technology and provided recommendations for standardizing use of this technology.
Antiplatelet therapy is used to manage cardiovascular events but can lead to increased risk for bleeding events both mild and severe.
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Transfusing activated platelets can increase the number of transfusions required and thus lead to additional costs compared with transfusing resting platelets.
This 2019 guideline update includes a review of new data on anticoagulant use and risk stratification in venous thromboembolism.
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.